Pioneering immune system researcher wins top lifetime achievement ... - Imperial College London
April 19, 2007 Imperial College London | Pioneering immune system researcher wins top lifetime achievement ... Imperial College London, UK - In 1992, the first series of successful trials were run with rheumatoid arthritis patients at the Kennedy Institute. The improvements in patients' health ... |
European Inventor of the Year Awards honour pioneering research - Cordis News
April 19, 2007 Cordis News | European Inventor of the Year Awards honour pioneering research Cordis News, Belgium - He was recognised for his identification of the role of cytokines in treatment for autoimmune disorders such as rheumatoid arthritis. ... European Inventor of the Year 2007 awards |
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon ... - Business Wire (press release)
April 19, 2007| Othera Pharmaceuticals Announces Upcoming Presentation Based Upon ... Business Wire (press release), CA - Subsequent animal studies confirmed that OT-551 treatment reduces levels of TNF-α, a key inflammatory cytokine that is regulated in large part by NF-kB. ... |
Critical Therapeutics Announces the Publication of New Preclincial ... - PharmaLive.com (press release)
April 19, 2007| Critical Therapeutics Announces the Publication of New Preclincial ... PharmaLive.com (press release), PA - Rheumatoid arthritis is one of the most serious and disabling forms of the disease, affecting about 2.1 million Americans. Lupus is a widespread and chronic ... |
Schering-Plough 1Q Profit Up 55 Percent - Forbes
April 19, 2007| Schering-Plough 1Q Profit Up 55 Percent Forbes, NY - ... is a treatment for immune-mediated inflammatory disorders that Schering-Plough markets in countries outside the United States for rheumatoid arthritis, ... Schering-Plough Reports Financial Results for First Quarter of 2007 Schering-Plough Reports Financial Results for First Quarter of 2007 |
Wyeth Reports Earnings Results for the 2007 First Quarter - MSN Money
April 19, 2007| Wyeth Reports Earnings Results for the 2007 First Quarter MSN Money - Enbrel is a breakthrough product approved for the treatment of chronic inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ... |
Wyeth Reports Earnings Results for the 2007 First Quarter - PharmaLive.com (press release)
April 19, 2007| Wyeth Reports Earnings Results for the 2007 First Quarter PharmaLive.com (press release), PA - Enbrel is a breakthrough product approved for the treatment of chronic inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ... |
EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers - PR Newswire (press release)
April 19, 2007| EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers PR Newswire (press release), NY - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
Schering-Plough's Net Rises 52% - Wall Street Journal (subscription)
April 19, 2007| Schering-Plough's Net Rises 52% Wall Street Journal (subscription), NY - Wyeth co-markets the treatment of rheumatoid arthritis and psoriasis with Amgen Inc., which primarily handles North American sales. ... |
Jamie Shane: Take time to find the right instructor - Naples Daily News
April 19, 2007| Jamie Shane: Take time to find the right instructor Naples Daily News, FL - I was at a young enough age where back problems, joint issues and rheumatoid arthritis were barely even phantom worries — regardless of how badly I treated ... |